RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Romero Del Rincón Celia, Gonzalez-Martinez Alicia, Quintas Sonia, García-Azorín David, Fernández Lázaro Iris, Guerrero-Peral Angel Luis, Gonzalez Osorio Yesica, Santos-Lasaosa Sonia, González Oria Carmen, Sánchez Rodríguez Norberto, Iglesias Díez Fernando, Echavarría Íñiguez Ana, Gil Luque Sendoa, Huerta-Villanueva Mariano, Campoy Díaz Sergio, Muñoz-Vendrell Albert, Lozano Ros Alberto, Sánchez-Soblechero Antonio, Velasco Juanes Fernando, Kortazar-Zubizarreta Izaro, Echeverría Amaya, Rodríguez-Vico Jaime, Jaimes Sánchez Alex, Gómez García Andrea, Morollón Sánchez-Mateos Noemí, Belvis Robert, Navarro Pérez María Pilar, García-Moncó Juan Carlos, Álvarez Escudero María Rocío, Montes Nuria, Gago-Veiga Ana Beatriz
Аннотация
METHODS: This was a prospective study conducted in 14 Headache Units in Spain. We included patients with response to anti-CGRP MAb with clinical worsening after withdrawal and resumption of treatment. Numbers of monthly migraine days (MMD) and monthly headache days (MHD) were obtained at four time points: before starting anti-CGRP MAb (T-baseline); last month of first treatment period (T-suspension); month of restart due to worsening (T-worsening); and 3 months after resumption (T-reintroduction). The response rate to resumption was calculated. Possible differences among periods were analysed according to MMD and MHD.
RESULTS: A total of 360 patients, 82% women, with a median (interquartile range [IQR]) age at migraine onset of 18 (12) years. The median (IQR) MHD at T-baseline was 20 (13) and MMD was 5 (6); at T-suspension, the median (IQR) MHD was 5 (6) and MMD was 4 (5); at T-worsening, the median (IQR) MHD was 16 (13) and MMD was 12 (6); and at T-reintroduction, the median (IQR) MHD was 8 (8) and MHD was 5 (5). In the second period of treatment, a 50% response rate was achieved by 57.4% of patients in MHD and 65.8% in MMD. Multivariate models showed significant differences in MHD between the third month after reintroduction and last month before suspension of first treatment period (p < 0.001).
CONCLUSION: The results suggest that anti-CGRP MAb therapy is effective after reintroduction. However, 3 months after resumption, one third of the sample reached the same improvement as after the first treatment period.